Key Takeaway
Updated meta-analysis of 12 studies (904 patients) found adjunctive NAC effectively reduces depressive symptoms, particularly in bipolar disorder, with optimal doses of 1,000-2,750 mg/day
Summary
This updated systematic review and meta-analysis evaluated NAC for depression in patients with psychiatric disorders including bipolar disorder and major depressive disorder. Twelve studies with 904 patients were included, with daily NAC doses ranging from 1,000 to 3,000 mg. Adjunctive NAC was found to effectively ameliorate depressive symptoms, particularly in bipolar disorder.
Methods
Systematic review and meta-analysis of RCTs. Included 12 studies with 904 patients. NAC doses ranged from 1,000-3,000 mg/day. Assessed as adjunctive treatment for depression in various psychiatric conditions. Published in General Hospital Psychiatry.
Key Results
Adjunctive NAC significantly reduced depressive symptoms across included studies. Benefits were most pronounced in bipolar disorder. Optimal dose range identified as 1,000-2,750 mg/day. NAC was well-tolerated with few adverse effects.
Limitations
Heterogeneous psychiatric populations (bipolar, MDD, mixed). Variable NAC dosing. Most studies assessed NAC as adjunctive rather than monotherapy. Moderate number of included studies. Publication bias possible. Limited long-term data.